N@N

Market Maker Surveillance Report. ECTE, CKGT, MCBC, CYPB, BSDM, SNMX, Winning Stocks With Lowest Price Friction For Tuesday, D

^{Published on 2010-12-14 19:00:18, Last Modified on 2010-12-22 19:41:48 - WOPRAI}
 

December 14, 2010 / M2 PRESSWIRE / BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Tuesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Tuesday there were 2560 companies with "abnormal" market making, 2329 companies with positive Friction Factors and 2861 companies with negative Friction Factors. Here is a list of the top companies with the largest percentage gain per share Tuesday and low price friction (bullish). This means that there was more buying than selling in the stocks and their stock prices rose faster with less Friction. ECHO THERAPEUTICS INC (OTCBB:ECTE), CHINA KANGTAI CACTUS BIO-TEC (OTCBB:CKGT), MACATAWA BANK CORP (NASDAQ:MCBC), CYPRESS BIOSCIENCE INC (NASDAQ:CYPB), BSD MEDICAL CORP (NASDAQ:BSDM), SENOMYX INC (NASDAQ:SNMX). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .

Market Maker Friction Factor is shown in the chart below:

     Symbol     Change       Percent      Buy Volume      Buy %%       Sell Volume     Sell %%      Net Volume      Friction
     ECTE       $0.210       18.58%       62,466          67.74%       29,750          32.26%       32,716          1,558   
     CKGT       $0.160       18.82%       247,892         56.61%       188,475         43.04%       59,417          3,714   
     MCBC       $0.690       22.55%       155,203         50.34%       153,114         49.66%       2,089           30      
     CYPB       $0.960       20.04%       2,430,956       50.73%       2,238,333       46.71%       192,623         2,006   
     BSDM       $1.560       41.71%       3,300,237       56.19%       2,557,521       43.55%       742,716         4,761   
     SNMX       $1.220       18.46%       348,358         50.35%       341,177         49.31%       7,181           59      

Analysis of the Friction Factor chart above shows that each of the six stocks mentioned above have high net buy volumes (buy volume, sell volume) and low price friction in their stocks. The Friction Factor displays how many more shares of buying than selling are required to move a stock higher by one cent or how many more shares of selling than buying moves a stock lower by 1 cent.

For example, the chart above shows SNMX with a dollar gain Tuesday of $1.22000 and a Friction Factor of 59 shares. That means that it only took 59 more shares of buying than selling to move SNMX higher by one penny. The Market Makers are currently allowing the stock to rise quickly (low friction). The combination of low friction and positive market direction can drive prices higher much faster than normal.

ECHO THERAPEUTICS INC (OTCBB:ECTE) - Echo Therapeutics, Inc., a medical device and specialty pharmaceutical company, engages in developing a non-invasive, wireless, and transdermal continuous glucose monitoring (tCGM) system for use in clinical settings and for people with diabetes, as well as a range of transdermal reformulations of specialty pharmaceutical products previously approved by the United States Food and Drug Administration (FDA). The company involves in developing its needle-free Prelude SkinPrep System (Prelude) for transdermal drug delivery, including topical lidocaine; and Symphony tCGM system (Symphony), a wireless and transdermal continuous glucose monitoring system designed to provide real-time blood glucose data. Its specialty pharmaceuticals pipeline is based on AzoneTS, a nontoxic, nonirritating skin penetration enhancer to enable topical application of FDA-approved prescription medications. The companys specialty pharmaceuticals include Durhalieve, an AzoneTS formulation of triamcinolone acetonide for the treatment of corticosteroid-responsive dermatoses. It has licensing agreements with Ferndale Pharma Group, Inc. to develop, market, sell, and distribute Prelude for skin preparation prior to a range of needle-based medical procedures in North America and the United Kingdom; and Handok Pharmaceuticals Co., Ltd. for developing, marketing, selling, and distributing Symphony to medical facilities and diabetics in South Korea. The company was founded in 1989 and is based in Franklin, Massachusetts.

CHINA KANGTAI CACTUS BIO-TEC (OTCBB:CKGT) - China Kangtai Cactus Bio-Tech Inc., through its subsidiaries, engages in the research, development, production, marketing, and sale of products derived from cacti. Its product lines include cactus nutraceuticals, and cactus nutritional food and drinks, as well as cactus raw and intermediate materials. The company's nutriceutical products containing cactus extracts include Cactus Protein Nutrient, Cactus Calcium Peptide Soft Capsule, and Cactus Shuxin Capsule. It also offers cactus beverage products, which include cactus beer, cactus fruit wine, cactus palm juices, and cactus fruit drinks; and cactus fish, cattle, and hog feed, as well as cactus tea, noodles, preserved bag vegetables, palm leaves, and cigarettes. In addition, the company provides cactus powder to pharmaceutical companies for use in medical products. It sells its products through provincial and municipal distributors and agents in Dalian, Heilongjiang, Harbin, Beijing, Guangzhou, Tianjin, Shenzhen, Jilin, Hebei, Liaoning, Shanxi, Hunan, Gansu, and Shandong in the People's Republic of China. The company is based in Harbin, the People's Republic of China.

MACATAWA BANK CORP (NASDAQ:MCBC) - Macatawa Bank Corporation operates as the holding company for Macatawa Bank that provides various commercial and personal banking services. It offers various deposit products, which comprise checking accounts, savings accounts, time deposits, transaction accounts, savings and time certificates, non-interest bearing and interest bearing demand deposits, and money market accounts. The companys loan portfolio comprises commercial and industrial loans, commercial real estate loans, construction and development loans, and multi-family and other non-residential real estate loans; residential mortgage loans; and consumer loans, including automobile loans, home equity lines of credit, installment loans, home improvement loans, deposit account loans, and other loans for household and personal purposes. It also provides cash management services, safe deposit boxes, travelers checks, money orders, and trust services; ATMs, Internet banking, telephone banking, and debit cards; and brokerage services, including discount brokerage, personal financial planning, and consultation regarding mutual funds. In addition, the company offers personal trust services, such as financial planning, investment management services, trust and estate administration, and custodial services; and retirement plan services, including provision of various qualified retirement plans, such as profit sharing, 401(k)s, and pension plans. It operated a network of 26 branches and a lending and operation service facility in Kent, Ottawa, and northern Allegan counties of Michigan. The company was founded in 1997 and is headquartered in Holland, Michigan.

CYPRESS BIOSCIENCE INC (NASDAQ:CYPB) - Cypress Bioscience, Inc. provides therapeutics and personalized medicine services in the United States. The company focuses on addressing the needs of physicians and their patients by identifying unmet medical needs in the areas of pain, rheumatology, and physical medicine and rehabilitation, including challenging disorders, such as fibromyalgia and rheumatoid arthritis. It offers Savella, a dual-reuptake inhibitor that preferentially blocks the reuptake of norepinephrine for the management of fibromyalgia. The company also provides personalized medicine services, including Avise MCV, a test that aids in the diagnosis and prognosis of rheumatoid arthritis; and Avise PG, a test that supports dose optimization and therapeutic decision making for patients taking methotrexate. Cypress Bioscience, Inc. has a license agreement with Pierre Fabre Medicament to develop and sell products with the compound milnacipran as an active ingredient for various indications in the United States and Canada; and a collaboration agreement with Forest Laboratories, Inc. for the development and marketing of milnacipran. The company was founded in 1981 and is based in San Diego, California.

BSD MEDICAL CORP (NASDAQ:BSDM) - BSD Medical Corporation develops, manufactures, markets, and services medical systems that deliver precision-focused radio frequency (RF) or microwave energy into diseased sites of the body, heating them to specified temperatures as required by a variety of medical therapies. The company develops technology and products for thermal ablation and hyperthermia cancer therapy through various techniques, which include thermal ablation that ablates soft tissues at high temperatures through focused microwave energy; superficial hyperthermia, which non-invasively treats cancerous tumors located within a few centimeters of the surface of the body, such as melanoma and recurrent breast cancer; internal or interstitial hyperthermia that treats tumors in combination with internal radiation therapy by inserting tiny microwave antennae that deliver hyperthermic microwave energy to tumors through the same catheters used to deliver radioactive materials to tumors for radiation therapy; and deep hyperthermia, which non-invasively treats tumors located deep within the body, including various problematic cancer sites located in the pelvis. It offers MicroThermX-100 microwave ablation system for ablation of soft tissue; MicroThermX-180 microwave ablation system that provides minimally invasive access to the target tissue, and could be used in open surgical, as well as in percutaneous ablation procedures; BSD-500 systems to deliver either superficial or interstitial hyperthermia therapy or both; and BSD-2000 family of products that non-invasively deliver localized therapeutic heating to solid tumors by applying RF energy to certain cancerous tumors, as well as BSD-2000/3D and BSD-2000/3D/MR. The company serves clinics, hospitals, and institutes that treat cancer in the United States and internationally. BSD Medical Corporation was founded in 1978 and is based in Salt Lake City, Utah.

SENOMYX INC (NASDAQ:SNMX) - Senomyx, Inc. engages in the discovery and development of flavor ingredients in the savory, sweet, salt, bitter, and cooling areas using proprietary taste receptor technologies. The company has product discovery, development, and commercialization collaborations with seven food, beverage, and ingredient supply companies: Ajinomoto Co., Inc., Cadbury plc, Campbell Soup Company, The Coca-Cola Company, Firmenich SA, Nestle SA, and Solae. Nestle is marketing products that contain one of Senomyxs flavor ingredients. Senomyx, Inc. licenses flavor ingredients to its collaborators on an exclusive or co-exclusive basis. It also has a collaborative research and license agreement with Campbell Soup Co. The company was founded in 1998 and is based in San Diego, California.

About BUYINS.NET

BUYINS.NET, www.buyins.net , monitors trading in all US stocks in real time and maintains massive databases of short sale and naked short sale time and sales data, short squeeze SqueezeTrigger prices, market maker price movements, shareholder data, statistical data on earnings, sector correlation, seasonality, hedge fund trading strategies, comparable valuations. Reports include:

REGULATORY & COMPLIANCE NEWS

Friction Factor -- market maker surveillance system tracking Level II market makers in all stocks to determine Price Friction and compliance with new "Fair Market Making Requirements"

RegSHO Naked Shorts -- tracks EVERY failure to deliver in all US stocks and tracks all Threshold Security Lists daily for which stocks have naked shorts that are not in compliance with Regulation SHO

INVESTMENTS & TRADING

SqueezeTrigger -- 29 billion cell database tracks EVERY short sale (not just total short interest) in all US stocks and calculates volume weighted price that a short squeeze will begin in each stock.

Earnings Edge -- predicts probability, price move and length of move before and after all US stock earnings reports.

Seasonality -- predicts probability, price move and length of move based on exact time of year for all US stocks.

Group Trader -- tracks sector rotation and stock correlation to its sector and predicts future moves in ALL sectors and industry groups.

Pattern Scan -- automates tracking of every technical pattern and predicts time and size of move in all stocks.

GATS (Global Automated Trading System) -- tracks all known trading strategies and qualifies and quantifies which are working best in real time.

DISCLAIMER:

BUYINS.NET is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell any securities. BUYINS.NET has not been compensated by any of the above mentioned companies. Past performance is not indicative of future results. Please visit our web site, www.buyins.net , for complete risks and disclosures.

Contact:

BUYINS.NET Thomas Ronk 800-715-9999 tom@buyins.net www.buyins.net